论文部分内容阅读
目的探讨复方苦参肠炎康片联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法选取2013年4月—2015年3月洛阳市第三人民医院收治的溃疡性结肠炎患者60例,根据治疗方法分为观察组与对照组,各30例。对照组患者予以美沙拉嗪治疗,观察组患者在对照组基础上予以复方苦参肠炎康片治疗。观察两组患者临床疗效、临床症状改善时间(止泻时间、退热时间、症状体征消失时间)、C反应蛋白(CRP)、血细胞沉降率(ESR)及不良反应发生情况及复发情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者止泻时间、退热时间、症状体征消失时间短于对照组,差异有统计学意义(P<0.05);两组患者CRP、ESR比较,差异无统计学意义(P>0.05);观察组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05);两组均未出现复发。结论复方苦参肠炎康片联合美沙拉嗪治疗溃疡性结肠炎的临床疗效显著,可改善患者临床症状,且不良反应少。
Objective To investigate the clinical curative effect of Compound Kashin Runchangkang Tablet and Mesalazine for treating ulcerative colitis. Methods Sixty patients with ulcerative colitis admitted to the Third People’s Hospital of Luoyang from April 2013 to March 2015 were selected and divided into the observation group and the control group according to the treatment method, with 30 cases in each group. The patients in the control group were treated with mesalazine, and the patients in the observation group were treated with Compound Kashin Runyankang Tablet on the basis of the control group. Clinical efficacy, clinical symptoms improvement time (diarrhea time, antipyretic time, disappearance of symptoms and signs), C-reactive protein (CRP), blood sedimentation rate (ESR) and incidence of adverse reactions and recurrence were observed. Results The total effective rate of the observation group was higher than that of the control group (P <0.05). The observation group had shorter diarrhea time, antipyretic time, shorter disappearance of symptoms and signs than the control group (P <0.05), and the difference was statistically significant (P <0.05). There was no significant difference in CRP and ESR between the two groups (P> 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, with significant difference (P <0.05) Recurrence. Conclusion Compound Kushen and Yankang tablets combined mesalazine treatment of ulcerative colitis clinical efficacy was significant, can improve the clinical symptoms of patients with fewer adverse reactions.